EGFR and non-small cell lung carcinoma: conducted a multi-institutional retrospective pooled analysis of 351 patients with EGFR-mutant NSCLC-developed brain metastases who received SRS followed by EGFR-TKI, WBRT followed by EGFR-TKI, or EGFR-TKI followed by SRS or WBRT at intracranial progression and found best overall survival times in patients who received SRS followed by EGFR-TKI compared to those who received whole brain radiotherapy first followed by EGFR tyrosine kinase inhibitors and to those who received EGFR tyrosine kinase inhibitor treatment first followed by SRS or whole brain radiotherapy (25).